All Stories

  1. Comparison of initial drug treatment of incident COPD patients with German treatment guidelines

    Article • September 2021, European Respiratory Society (ERS)

    Claus Vogelmeier

  2. Risk of future exacerbations among COPD patients – a real-world register-based cohort study (AvoidEx)

    Article • September 2020, European Respiratory Society (ERS)

    Claus Vogelmeier

  3. Diagnosing Alpha-1-Antitrypsin Deficiency Using A PCR/Luminescence-Based Technology

    Article • International Journal of Chronic Obstructive Pulmonary Disease, November 2019, Taylor & Francis

    robert bals, Claus Vogelmeier

  4. Adherence To Respiratory And Nonrespiratory Medication In Patients With COPD: Results Of The German COSYCONET Cohort

    Article • Patient Preference and Adherence, October 2019, Taylor & Francis

    robert bals, Claus Vogelmeier

  5. Umeclidinium/vilanterol in preventing clinically important deterioration (CID) in COPD and impact of baseline disease severity: the EMAX trial

    Article • September 2019, European Respiratory Society (ERS)

    Claus Vogelmeier

  6. The frequent exacerbator in real-life: an analysis of the DACCORD study

    Article • September 2019, European Respiratory Society (ERS)

    Claus Vogelmeier

  7. Prevalence of cardiac comorbidities, and their underdetection and contribution to exertional symptoms in COPD: results from the COSYCONET cohort

    Article • International Journal of Chronic Obstructive Pulmonary Disease, September 2019, Taylor & Francis

    robert bals, Claus Vogelmeier, Dr. Benjamin Waschki

  8. Determinants of healthcare utilization and costs in COPD patients: first longitudinal results from the German COPD cohort COSYCONET

    Article • International Journal of Chronic Obstructive Pulmonary Disease, July 2019, Dove Medical Press

    Claus Vogelmeier

  9. Personalized medicine for patients with COPD: where are we?

    Article • International Journal of Chronic Obstructive Pulmonary Disease, July 2019, Dove Medical Press

    Dr Frits M.E. Franssen, Claus Vogelmeier

  10. Inhaled corticosteroid use by exacerbations and eosinophils: a real-world COPD population

    Article • International Journal of Chronic Obstructive Pulmonary Disease, April 2019, Dove Medical Press

    Jørgen Vestbo, Claus Vogelmeier, Dr. Konstantinos Kostikas

  11. Longitudinal stability of blood eosinophil count strata in the COPD COSYCONET cohort

    Article • International Journal of Chronic Obstructive Pulmonary Disease, September 2018, Dove Medical Press

    Sebastian Fähndrich, robert bals, Claus Vogelmeier

  12. COPD as a risk factor of the complications in lower limb arthroplasty: a patient-matched study

    Article • International Journal of Chronic Obstructive Pulmonary Disease, August 2018, Dove Medical Press

    Claus Vogelmeier

  13. Influence of body mass on predicted values of static hyperinflation in COPD

    Article • International Journal of Chronic Obstructive Pulmonary Disease, August 2018, Dove Medical Press

    Professor Klaus F. Rabe, Claus Vogelmeier

  14. Dual bronchodilation vs triple therapy in the “real-life” COPD DACCORD study

    Article • International Journal of Chronic Obstructive Pulmonary Disease, August 2018, Dove Medical Press

    Dr Peter Kardos, Claus Vogelmeier, Dr. Konstantinos Kostikas, Nadine Lossi

  15. Health status in patients with COPD treated with roflumilast: two large noninterventional real-life studies: DINO and DACOTA

    Article • International Journal of Chronic Obstructive Pulmonary Disease, May 2018, Dove Medical Press

    Claus Vogelmeier

  16. COPD exacerbation rates with IND/GLY

    Article • International Journal of Chronic Obstructive Pulmonary Disease, April 2018, Dove Medical Press

    Claus Vogelmeier, Professor Kenneth R Chapman, Dr. Konstantinos Kostikas, Jørgen Vestbo

  17. Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study

    Article • International Journal of Chronic Obstructive Pulmonary Disease, April 2018, Dove Medical Press

    Dr. Konstantinos Kostikas, Nadine Lossi, Mina Gaga, Claus Vogelmeier

  18. The contribution of symptoms and comorbidities to the economic impact of COPD: an analysis of the German COSYCONET cohort

    Article • International Journal of Chronic Obstructive Pulmonary Disease, December 2017, Dove Medical Press

    Claus Vogelmeier

  19. Perception of symptoms and quality of life – comparison of patients’ and physicians’ views in the COPD MIRROR study

    Article • International Journal of Chronic Obstructive Pulmonary Disease, July 2017, Dove Medical Press

    Professor francesco blasi, Valeria Pegoraro, Claus Vogelmeier, Mina Gaga, Alvar Agustí

  20. The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD

    Article • International Journal of Chronic Obstructive Pulmonary Disease, May 2017, Dove Medical Press

    Dr. Konstantinos Kostikas, giovanni bader, Claus Vogelmeier

  21. Deterioration of quality of life is associated with the exacerbation frequency in individuals with alpha-1-antitrypsin deficiency – analysis from the German Registry

    Article • International Journal of Chronic Obstructive Pulmonary Disease, May 2017, Dove Medical Press

    Dr Philipp M Lepper, Sebastian Fähndrich, Claus Vogelmeier, robert bals

  22. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary

    Article • American Review of Respiratory Disease, March 2017, American Thoracic Society

    Claus Vogelmeier

  23. “Real-life” inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD

    Article • International Journal of Chronic Obstructive Pulmonary Disease, February 2017, Dove Medical Press

    Dr Peter Kardos, Nadine Lossi, Claus Vogelmeier

  24. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary

    Article • European Respiratory Journal, January 2017, European Respiratory Society (ERS)

    Claus Vogelmeier

  25. Indacaterol/glycopyrronium in symptomatic patients with COPD (GOLD B and GOLD D) versus salmeterol/fluticasone: ILLUMINATE/LANTERN pooled analysis

    Article • International Journal of Chronic Obstructive Pulmonary Disease, December 2016, Dove Medical Press

    giovanni bader, Michael Humphries, Claus Vogelmeier

  26. Efficacy and safety of aclidinium/formoterolversussalmeterol/fluticasone: a phase 3 COPD study

    Article • European Respiratory Journal, August 2016, European Respiratory Society (ERS)

    dr anne leselbaum, Claus Vogelmeier

  27. A year in the life of German patients with COPD: the DACCORD observational study

    Article • International Journal of Chronic Obstructive Pulmonary Disease, July 2016, Dove Medical Press

    Dr Peter Kardos, Nadine Lossi, Claus Vogelmeier

  28. Highlights and hot topics in the management of COPD: where are we heading?

    Article • International Journal of Chronic Obstructive Pulmonary Disease, February 2016, Dove Medical Press

    Claus Vogelmeier

  29. The effects of weekly augmentation therapy in patients with PiZZ α1-antitrypsin deficiency

    Article • International Journal of Chronic Obstructive Pulmonary Disease, September 2012, Taylor & Francis

    Dr Elena Miranda, Rembert Koczulla, Claus Vogelmeier